Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time

Summary Treatment with the direct thrombin inhibitor argatroban (ARG) is often followed by vitamin K-antagonist treatment (VKA). Phenprocoumon (PC) and acenocoumarol (AC) are frequently used in Europe. The standard monitoring test for VKA, prothrombin time (PT), is prolonged by direct thrombin inhib...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thrombosis and haemostasis 2004-06, Vol.91 (6), p.1137-1145
Hauptverfasser: Harder, Sebastian, Graff, Jochen, Klinkhardt, Ute, von Hentig, Nils, Walenga, Jeanine M., Watanabe, Hikari, Osakabe, Masanori, Breddin, Hans-Klaus
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1145
container_issue 6
container_start_page 1137
container_title Thrombosis and haemostasis
container_volume 91
creator Harder, Sebastian
Graff, Jochen
Klinkhardt, Ute
von Hentig, Nils
Walenga, Jeanine M.
Watanabe, Hikari
Osakabe, Masanori
Breddin, Hans-Klaus
description Summary Treatment with the direct thrombin inhibitor argatroban (ARG) is often followed by vitamin K-antagonist treatment (VKA). Phenprocoumon (PC) and acenocoumarol (AC) are frequently used in Europe. The standard monitoring test for VKA, prothrombin time (PT), is prolonged by direct thrombin inhibitors. Therefore the International Normalized Ratio (INR) obtained during combined treatment does not reflect the true effect of the VKA. A similar interference of the VKA on the activated partial thromboplastin time (aPTT), a monitoring assay for direct thrombin inhibitors, can occur. In 39 healthy volunteers the effect of ARG alone or combined with PC or AC on PT, INR, aPTT, and Ecarin Clotting Time (ECT) was investigated. 6 groups each of 6-8 volunteers received a 5-hour infusion of either 1.0, 2.0 or 3.0 µg/kg/min ARG (days 1, 3, 4 and 5) before initiation of either PC or AC (day 1) and during continued VKA dosing (target INR 2-3). A linear relationship (INR ARG+VKA = intercept + slope * INR VKA alone ) was observed between the INR measured “on” and “off” ARG.The slope depended on the argatroban dose and on the International Sensitivity Index (ISI) of the PT reagent, the steepest slope (i.e., the largest difference between INR ARG+VKA and INR VKA alone ) was seen with the highest ARG dose and the PT reagent with an ISI of 2.13.There was a close correlation between plasma levels of ARG and aPTT or ECT. Under VKA the ARG-aPTT relationship indicated an increased sensitivity of the aPTT to ARG, VKA treatment had no effect on the prolongation of the ECT induced by argatroban. In conclusion, ARG at doses up to 2 µg/kg/min can be discontinued at an INR of 4.0 on combined therapy with VKA, as this would correspond to an INR between 2.2 and 3.7 for the VKA. If it is necessary to monitor ARG in the critical transition period, the ECT which is not influenced by VKA can be used as an alternative to the aPTT.
doi_str_mv 10.1160/TH03-12-0794
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71981971</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71981971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4584-9968eea2402347d7f7e65bca5823a210cca6ecd6cd48abc250eeba2c80b7bd003</originalsourceid><addsrcrecordid>eNqtkk9v1DAQxSMEoqVw44x8gQsN2M4fJ72hVaFIlbgsEjdr4kw2rhI72E4rvhcfkNnuiiIkbpys8fvpPXmes-yl4O-EqPn77RUvciFzrtryUXYqq1rlddN-e5yd8qLkeS3L6iR7FuMN56Iu2-ppdiIqoaqG89Ps5zaAizZZ79gQ_Mwg7CAF34FjyTMfYGLgkjUedusE99ydTSNbRnRL8MavM135wMCgux8h-OmC4TCgSZGRSFgaybuz5GlnPCc22VtI2LMFQrKUcQD8MkFMD5jr2aWBQBebyScSdmxLyvPsyQBTxBfH8yz7-vFyu7nKr798-rz5cJ2bsmrKvG3rBhFkyWVRql4NCuuqM1A1sgApuDFQo-lr05cNdEZWHLEDaRreqa7nvDjL3hx86QXfV4xJzzYanCZw6NeolWgb0SpB4PkBNMHHGHDQS7C0iB9acL1vSe9b0kLqfUuEvzr6rt2M_QN8rIWA10cAooFpoI6MjX9wTVHJoiDu7YFLo8UZ9Y1fg6ON_CvWHuhoRkgJVgy_LY_7j5RCW9cj4Oxjgv1svEvoEgnBjPYWtY1xRa1Uo2dwazTBLkkXqi51HP2dHtM8UZb5j1lxQUO_5O-84he5wv6w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71981971</pqid></control><display><type>article</type><title>Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time</title><source>Thieme - Connect here FIRST to enable access</source><source>MEDLINE</source><creator>Harder, Sebastian ; Graff, Jochen ; Klinkhardt, Ute ; von Hentig, Nils ; Walenga, Jeanine M. ; Watanabe, Hikari ; Osakabe, Masanori ; Breddin, Hans-Klaus</creator><creatorcontrib>Harder, Sebastian ; Graff, Jochen ; Klinkhardt, Ute ; von Hentig, Nils ; Walenga, Jeanine M. ; Watanabe, Hikari ; Osakabe, Masanori ; Breddin, Hans-Klaus</creatorcontrib><description>Summary Treatment with the direct thrombin inhibitor argatroban (ARG) is often followed by vitamin K-antagonist treatment (VKA). Phenprocoumon (PC) and acenocoumarol (AC) are frequently used in Europe. The standard monitoring test for VKA, prothrombin time (PT), is prolonged by direct thrombin inhibitors. Therefore the International Normalized Ratio (INR) obtained during combined treatment does not reflect the true effect of the VKA. A similar interference of the VKA on the activated partial thromboplastin time (aPTT), a monitoring assay for direct thrombin inhibitors, can occur. In 39 healthy volunteers the effect of ARG alone or combined with PC or AC on PT, INR, aPTT, and Ecarin Clotting Time (ECT) was investigated. 6 groups each of 6-8 volunteers received a 5-hour infusion of either 1.0, 2.0 or 3.0 µg/kg/min ARG (days 1, 3, 4 and 5) before initiation of either PC or AC (day 1) and during continued VKA dosing (target INR 2-3). A linear relationship (INR ARG+VKA = intercept + slope * INR VKA alone ) was observed between the INR measured “on” and “off” ARG.The slope depended on the argatroban dose and on the International Sensitivity Index (ISI) of the PT reagent, the steepest slope (i.e., the largest difference between INR ARG+VKA and INR VKA alone ) was seen with the highest ARG dose and the PT reagent with an ISI of 2.13.There was a close correlation between plasma levels of ARG and aPTT or ECT. Under VKA the ARG-aPTT relationship indicated an increased sensitivity of the aPTT to ARG, VKA treatment had no effect on the prolongation of the ECT induced by argatroban. In conclusion, ARG at doses up to 2 µg/kg/min can be discontinued at an INR of 4.0 on combined therapy with VKA, as this would correspond to an INR between 2.2 and 3.7 for the VKA. If it is necessary to monitor ARG in the critical transition period, the ECT which is not influenced by VKA can be used as an alternative to the aPTT.</description><identifier>ISSN: 0340-6245</identifier><identifier>EISSN: 2567-689X</identifier><identifier>DOI: 10.1160/TH03-12-0794</identifier><identifier>PMID: 15175800</identifier><identifier>CODEN: THHADQ</identifier><language>eng</language><publisher>Stuttgart: Schattauer Verlag für Medizin und Naturwissenschaften</publisher><subject>Acenocoumarol - administration &amp; dosage ; Administration, Oral ; Adult ; Anticoagulants - administration &amp; dosage ; Anticoagulants - blood ; Biological and medical sciences ; Blood Coagulation - drug effects ; Blood Coagulation Tests ; Blood Coagulation, Fibrinolysis and Cellular Haemostasis ; Blood coagulation. Blood cells ; Drug Monitoring - methods ; Drug Monitoring - standards ; Drug Therapy, Combination ; Endopeptidases ; Fundamental and applied biological sciences. Psychology ; Hematologic and hematopoietic diseases ; Humans ; International Normalized Ratio ; Male ; Medical sciences ; Molecular and cellular biology ; Partial Thromboplastin Time ; Phenprocoumon - administration &amp; dosage ; Pipecolic Acids - administration &amp; dosage ; Platelet diseases and coagulopathies ; Prothrombin Time ; Regression Analysis ; Statistical Distributions</subject><ispartof>Thrombosis and haemostasis, 2004-06, Vol.91 (6), p.1137-1145</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4584-9968eea2402347d7f7e65bca5823a210cca6ecd6cd48abc250eeba2c80b7bd003</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.thieme-connect.de/products/ejournals/pdf/10.1160/TH03-12-0794.pdf$$EPDF$$P50$$Gthieme$$H</linktopdf><linktohtml>$$Uhttps://www.thieme-connect.de/products/ejournals/html/10.1160/TH03-12-0794$$EHTML$$P50$$Gthieme$$H</linktohtml><link.rule.ids>314,776,780,3004,27903,27904,54537,54538</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15835233$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15175800$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Harder, Sebastian</creatorcontrib><creatorcontrib>Graff, Jochen</creatorcontrib><creatorcontrib>Klinkhardt, Ute</creatorcontrib><creatorcontrib>von Hentig, Nils</creatorcontrib><creatorcontrib>Walenga, Jeanine M.</creatorcontrib><creatorcontrib>Watanabe, Hikari</creatorcontrib><creatorcontrib>Osakabe, Masanori</creatorcontrib><creatorcontrib>Breddin, Hans-Klaus</creatorcontrib><title>Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time</title><title>Thrombosis and haemostasis</title><addtitle>Thromb Haemost</addtitle><description>Summary Treatment with the direct thrombin inhibitor argatroban (ARG) is often followed by vitamin K-antagonist treatment (VKA). Phenprocoumon (PC) and acenocoumarol (AC) are frequently used in Europe. The standard monitoring test for VKA, prothrombin time (PT), is prolonged by direct thrombin inhibitors. Therefore the International Normalized Ratio (INR) obtained during combined treatment does not reflect the true effect of the VKA. A similar interference of the VKA on the activated partial thromboplastin time (aPTT), a monitoring assay for direct thrombin inhibitors, can occur. In 39 healthy volunteers the effect of ARG alone or combined with PC or AC on PT, INR, aPTT, and Ecarin Clotting Time (ECT) was investigated. 6 groups each of 6-8 volunteers received a 5-hour infusion of either 1.0, 2.0 or 3.0 µg/kg/min ARG (days 1, 3, 4 and 5) before initiation of either PC or AC (day 1) and during continued VKA dosing (target INR 2-3). A linear relationship (INR ARG+VKA = intercept + slope * INR VKA alone ) was observed between the INR measured “on” and “off” ARG.The slope depended on the argatroban dose and on the International Sensitivity Index (ISI) of the PT reagent, the steepest slope (i.e., the largest difference between INR ARG+VKA and INR VKA alone ) was seen with the highest ARG dose and the PT reagent with an ISI of 2.13.There was a close correlation between plasma levels of ARG and aPTT or ECT. Under VKA the ARG-aPTT relationship indicated an increased sensitivity of the aPTT to ARG, VKA treatment had no effect on the prolongation of the ECT induced by argatroban. In conclusion, ARG at doses up to 2 µg/kg/min can be discontinued at an INR of 4.0 on combined therapy with VKA, as this would correspond to an INR between 2.2 and 3.7 for the VKA. If it is necessary to monitor ARG in the critical transition period, the ECT which is not influenced by VKA can be used as an alternative to the aPTT.</description><subject>Acenocoumarol - administration &amp; dosage</subject><subject>Administration, Oral</subject><subject>Adult</subject><subject>Anticoagulants - administration &amp; dosage</subject><subject>Anticoagulants - blood</subject><subject>Biological and medical sciences</subject><subject>Blood Coagulation - drug effects</subject><subject>Blood Coagulation Tests</subject><subject>Blood Coagulation, Fibrinolysis and Cellular Haemostasis</subject><subject>Blood coagulation. Blood cells</subject><subject>Drug Monitoring - methods</subject><subject>Drug Monitoring - standards</subject><subject>Drug Therapy, Combination</subject><subject>Endopeptidases</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>International Normalized Ratio</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Molecular and cellular biology</subject><subject>Partial Thromboplastin Time</subject><subject>Phenprocoumon - administration &amp; dosage</subject><subject>Pipecolic Acids - administration &amp; dosage</subject><subject>Platelet diseases and coagulopathies</subject><subject>Prothrombin Time</subject><subject>Regression Analysis</subject><subject>Statistical Distributions</subject><issn>0340-6245</issn><issn>2567-689X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqtkk9v1DAQxSMEoqVw44x8gQsN2M4fJ72hVaFIlbgsEjdr4kw2rhI72E4rvhcfkNnuiiIkbpys8fvpPXmes-yl4O-EqPn77RUvciFzrtryUXYqq1rlddN-e5yd8qLkeS3L6iR7FuMN56Iu2-ppdiIqoaqG89Ps5zaAizZZ79gQ_Mwg7CAF34FjyTMfYGLgkjUedusE99ydTSNbRnRL8MavM135wMCgux8h-OmC4TCgSZGRSFgaybuz5GlnPCc22VtI2LMFQrKUcQD8MkFMD5jr2aWBQBebyScSdmxLyvPsyQBTxBfH8yz7-vFyu7nKr798-rz5cJ2bsmrKvG3rBhFkyWVRql4NCuuqM1A1sgApuDFQo-lr05cNdEZWHLEDaRreqa7nvDjL3hx86QXfV4xJzzYanCZw6NeolWgb0SpB4PkBNMHHGHDQS7C0iB9acL1vSe9b0kLqfUuEvzr6rt2M_QN8rIWA10cAooFpoI6MjX9wTVHJoiDu7YFLo8UZ9Y1fg6ON_CvWHuhoRkgJVgy_LY_7j5RCW9cj4Oxjgv1svEvoEgnBjPYWtY1xRa1Uo2dwazTBLkkXqi51HP2dHtM8UZb5j1lxQUO_5O-84he5wv6w</recordid><startdate>200406</startdate><enddate>200406</enddate><creator>Harder, Sebastian</creator><creator>Graff, Jochen</creator><creator>Klinkhardt, Ute</creator><creator>von Hentig, Nils</creator><creator>Walenga, Jeanine M.</creator><creator>Watanabe, Hikari</creator><creator>Osakabe, Masanori</creator><creator>Breddin, Hans-Klaus</creator><general>Schattauer Verlag für Medizin und Naturwissenschaften</general><general>Schattauer GmbH</general><general>Schattauer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200406</creationdate><title>Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time</title><author>Harder, Sebastian ; Graff, Jochen ; Klinkhardt, Ute ; von Hentig, Nils ; Walenga, Jeanine M. ; Watanabe, Hikari ; Osakabe, Masanori ; Breddin, Hans-Klaus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4584-9968eea2402347d7f7e65bca5823a210cca6ecd6cd48abc250eeba2c80b7bd003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Acenocoumarol - administration &amp; dosage</topic><topic>Administration, Oral</topic><topic>Adult</topic><topic>Anticoagulants - administration &amp; dosage</topic><topic>Anticoagulants - blood</topic><topic>Biological and medical sciences</topic><topic>Blood Coagulation - drug effects</topic><topic>Blood Coagulation Tests</topic><topic>Blood Coagulation, Fibrinolysis and Cellular Haemostasis</topic><topic>Blood coagulation. Blood cells</topic><topic>Drug Monitoring - methods</topic><topic>Drug Monitoring - standards</topic><topic>Drug Therapy, Combination</topic><topic>Endopeptidases</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>International Normalized Ratio</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Molecular and cellular biology</topic><topic>Partial Thromboplastin Time</topic><topic>Phenprocoumon - administration &amp; dosage</topic><topic>Pipecolic Acids - administration &amp; dosage</topic><topic>Platelet diseases and coagulopathies</topic><topic>Prothrombin Time</topic><topic>Regression Analysis</topic><topic>Statistical Distributions</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Harder, Sebastian</creatorcontrib><creatorcontrib>Graff, Jochen</creatorcontrib><creatorcontrib>Klinkhardt, Ute</creatorcontrib><creatorcontrib>von Hentig, Nils</creatorcontrib><creatorcontrib>Walenga, Jeanine M.</creatorcontrib><creatorcontrib>Watanabe, Hikari</creatorcontrib><creatorcontrib>Osakabe, Masanori</creatorcontrib><creatorcontrib>Breddin, Hans-Klaus</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harder, Sebastian</au><au>Graff, Jochen</au><au>Klinkhardt, Ute</au><au>von Hentig, Nils</au><au>Walenga, Jeanine M.</au><au>Watanabe, Hikari</au><au>Osakabe, Masanori</au><au>Breddin, Hans-Klaus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time</atitle><jtitle>Thrombosis and haemostasis</jtitle><addtitle>Thromb Haemost</addtitle><date>2004-06</date><risdate>2004</risdate><volume>91</volume><issue>6</issue><spage>1137</spage><epage>1145</epage><pages>1137-1145</pages><issn>0340-6245</issn><eissn>2567-689X</eissn><coden>THHADQ</coden><abstract>Summary Treatment with the direct thrombin inhibitor argatroban (ARG) is often followed by vitamin K-antagonist treatment (VKA). Phenprocoumon (PC) and acenocoumarol (AC) are frequently used in Europe. The standard monitoring test for VKA, prothrombin time (PT), is prolonged by direct thrombin inhibitors. Therefore the International Normalized Ratio (INR) obtained during combined treatment does not reflect the true effect of the VKA. A similar interference of the VKA on the activated partial thromboplastin time (aPTT), a monitoring assay for direct thrombin inhibitors, can occur. In 39 healthy volunteers the effect of ARG alone or combined with PC or AC on PT, INR, aPTT, and Ecarin Clotting Time (ECT) was investigated. 6 groups each of 6-8 volunteers received a 5-hour infusion of either 1.0, 2.0 or 3.0 µg/kg/min ARG (days 1, 3, 4 and 5) before initiation of either PC or AC (day 1) and during continued VKA dosing (target INR 2-3). A linear relationship (INR ARG+VKA = intercept + slope * INR VKA alone ) was observed between the INR measured “on” and “off” ARG.The slope depended on the argatroban dose and on the International Sensitivity Index (ISI) of the PT reagent, the steepest slope (i.e., the largest difference between INR ARG+VKA and INR VKA alone ) was seen with the highest ARG dose and the PT reagent with an ISI of 2.13.There was a close correlation between plasma levels of ARG and aPTT or ECT. Under VKA the ARG-aPTT relationship indicated an increased sensitivity of the aPTT to ARG, VKA treatment had no effect on the prolongation of the ECT induced by argatroban. In conclusion, ARG at doses up to 2 µg/kg/min can be discontinued at an INR of 4.0 on combined therapy with VKA, as this would correspond to an INR between 2.2 and 3.7 for the VKA. If it is necessary to monitor ARG in the critical transition period, the ECT which is not influenced by VKA can be used as an alternative to the aPTT.</abstract><cop>Stuttgart</cop><pub>Schattauer Verlag für Medizin und Naturwissenschaften</pub><pmid>15175800</pmid><doi>10.1160/TH03-12-0794</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0340-6245
ispartof Thrombosis and haemostasis, 2004-06, Vol.91 (6), p.1137-1145
issn 0340-6245
2567-689X
language eng
recordid cdi_proquest_miscellaneous_71981971
source Thieme - Connect here FIRST to enable access; MEDLINE
subjects Acenocoumarol - administration & dosage
Administration, Oral
Adult
Anticoagulants - administration & dosage
Anticoagulants - blood
Biological and medical sciences
Blood Coagulation - drug effects
Blood Coagulation Tests
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Blood coagulation. Blood cells
Drug Monitoring - methods
Drug Monitoring - standards
Drug Therapy, Combination
Endopeptidases
Fundamental and applied biological sciences. Psychology
Hematologic and hematopoietic diseases
Humans
International Normalized Ratio
Male
Medical sciences
Molecular and cellular biology
Partial Thromboplastin Time
Phenprocoumon - administration & dosage
Pipecolic Acids - administration & dosage
Platelet diseases and coagulopathies
Prothrombin Time
Regression Analysis
Statistical Distributions
title Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T21%3A42%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transition%20from%20argatroban%20to%20oral%20anticoagulation%20with%20phenprocoumon%20or%20acenocoumarol:%20effects%20on%20prothrombin%20time,%20activated%20partial%20thromboplastin%20time,%20and%20Ecarin%20Clotting%20Time&rft.jtitle=Thrombosis%20and%20haemostasis&rft.au=Harder,%20Sebastian&rft.date=2004-06&rft.volume=91&rft.issue=6&rft.spage=1137&rft.epage=1145&rft.pages=1137-1145&rft.issn=0340-6245&rft.eissn=2567-689X&rft.coden=THHADQ&rft_id=info:doi/10.1160/TH03-12-0794&rft_dat=%3Cproquest_cross%3E71981971%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71981971&rft_id=info:pmid/15175800&rfr_iscdi=true